News Posts List
VIDEO: Kidney Cancer News
02/09/2011
Learn about the MDX-1106 clinical trial and proposed funding cuts for NIH/NCI in our daily newscast.
Health Law Changes May Harm Patients And Doctors
02/08/2011
Dr. Martha Boone, an Atlanta urologist, explains the consequences of the new health care law. Because of her fears about Obamacare, Boone moved to a less-expensive office so she could avoid dropping Medicare patients or laying off an employee.
Aveo Pharma gets USAN name for novel, internally discovered anti-HGF/c-MET pathway antibody
02/08/2011
Aveo Pharmaceuticals, Inc. announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name ‘ficlatuzumab’ (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
Kidney Cancer Survivor: U.S. Sen. Roy Blunt
02/07/2011
WSJ: An ObamaCare Appeal From the States
02/07/2011
If there's to be a train wreck, we governors would rather be spectators than conductors. But if the federal government is willing to reroute the train to a different, more productive track, we are here to help.
NEW: Kidney Cancer Newsletter Online
02/05/2011
The current edition of Kidney Cancer News, the Association's period newsletter, is available online.
EntreMed's ENMD-2076 Phase 1 Results
02/05/2011
EntreMed, Inc. (Nasdaq:ENMD - News), today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor.
Update Knowledge of Kidney Cancer
02/03/2011
"To this end, we developed a high-throughput screen to identify small molecules derived from plants, microorganisms, and marine organisms to which CCRCC cells are sensitive. Screening over 8,000 compounds using this approach, we report here the identification of the microbially derived compound carminomycin I (CA) as an effective inhibitor of VHL-defective (VHL(-/-)) CCRCC cell proliferation..."
How Safe Is Bevacizumab?
02/02/2011
What is undoubtedly clear is that 10 years ago, as we peered into the crystal ball of targeted therapies, enormous toxicities and questionable outcomes were not what we expected.
News Feed